Galapagos Initiates Drug Discovery Collaboration With SPRI

Galapagos, a drug discovery and development company, has announced that its service division, BioFocus DPI, has initiated a drug discovery collaboration with Schering-Plough Research Institute, the human pharmaceutical research unit of Schering-Plough Corporation.

Under the terms of the agreement, BioFocus DPI will perform medicinal chemistry with supporting biology and ADME/PK services for multiple Schering-Plough drug discovery projects. Total contract value for Galapagos is E2.8 million over a one-year period.

Building on a collaboration established in May 2009 and expanded in September 2009, BioFocus DPI scientists will work with two of Schering-Plough Research Institute's (SPRI's) European sites on these drug discovery projects.

Onno van de Stolpe, CEO of Galapagos, said: "BioFocus DPI has proven resilient in securing large collaborations with strong partners, amidst consolidation and reorganization in the pharma industry."

SOURCE: Galapagos